Search

Your search keyword '"K. Biton"' showing total 3 results
Start Over Author "K. Biton"
3 results on '"K. Biton"'

1. Reducing perioperative anxiety in patients undergoing transurethral resection of bladder tumor by acupuncture treatment: A prospective randomized controlled study

Author

E. Schiff, Sagi Shprits, K. Biton, G. Meyer, N. Stoppelman, S. Attias, D. Avshalomov, Sarel Halachmi, and Ofer Nativ

Subjects
medicine.medical_specialty, business.industry, Urology, Perioperative, Acupuncture treatment, Surgery, Resection, law.invention, Randomized controlled trial, law, medicine, Bladder tumor, Anxiety, In patient, medicine.symptom, business
Published
2019
Full Text
View/download PDF

2. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients

Author

G. Meyer, Alexander Kastin, Ofer Nativ, Boaz Moskovitz, K. Biton, M. Gross, and A. Kravtzov

Subjects
Adult, Male, medicine.medical_specialty, Mitomycin, Thermo chemotherapy, Risk Factors, Ablative case, medicine, Humans, Aged, Aged, 80 and over, Bladder cancer, business.industry, Mitomycin C, Treatment options, Hematology, Hyperthermia, Induced, Middle Aged, medicine.disease, Surgery, Transitional cell carcinoma, Oncology, Urinary Bladder Neoplasms, Local Hyperthermia, Superficial bladder cancer, Female, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background The purpose of this study was to evaluate the efficacy of combined local hyperthermia and intravesical mitomycin-C (MMC) in a selected group of patients with intermediate or high-risk recurrent transitional cell carcinoma (TCC) of bladder. Patients and methods Forty-seven patients with multiple or recurrent Ta or T1 TCC of the bladder were treated with intravesical MMC and local hyperthermia of the bladder wall. Patients were treated with either a prophylactic protocol (40 mg MMC) after complete transurethral resection of all tumours or with an ablative protocol (80 mg MMC) in patients with viable tumours. Results Thirty-two patients were eligible for analysis. The prophylactic protocol was administered to 22 patients. After a mean follow-up of 289 days, 20 patients (91%) were recurrence free. Two patients (9%) had tumour recurrence after a mean period of 431 days. The ablative protocol was administered to 10 patients. Complete tumour ablation was achieved in eight patients (80%) after a mean follow up of 104.5 days. Conclusions Our efficacy and safety results confirm those reported in previously published studies, suggesting the promising value of this combined treatment modality for both prophylactic and ablative patients. The ablative protocol offers an alternative therapy for a selected patient population for whom no other treatment option exists.

Published
2005

3. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients.

Author

Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, and Nativ O

Subjects
Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Male, Middle Aged, Risk Factors, Urinary Bladder Neoplasms drug therapy, Urinary Bladder Neoplasms pathology, Hyperthermia, Induced methods, Mitomycin therapeutic use, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local therapy, Urinary Bladder Neoplasms therapy
Abstract

Background: The purpose of this study was to evaluate the efficacy of combined local hyperthermia and intravesical mitomycin-C (MMC) in a selected group of patients with intermediate or high-risk recurrent transitional cell carcinoma (TCC) of bladder., Patients and Methods: Forty-seven patients with multiple or recurrent Ta or T1 TCC of the bladder were treated with intravesical MMC and local hyperthermia of the bladder wall. Patients were treated with either a prophylactic protocol (40 mg MMC) after complete transurethral resection of all tumours or with an ablative protocol (80 mg MMC) in patients with viable tumours., Results: Thirty-two patients were eligible for analysis. The prophylactic protocol was administered to 22 patients. After a mean follow-up of 289 days, 20 patients (91%) were recurrence free. Two patients (9%) had tumour recurrence after a mean period of 431 days. The ablative protocol was administered to 10 patients. Complete tumour ablation was achieved in eight patients (80%) after a mean follow up of 104.5 days., Conclusions: Our efficacy and safety results confirm those reported in previously published studies, suggesting the promising value of this combined treatment modality for both prophylactic and ablative patients. The ablative protocol offers an alternative therapy for a selected patient population for whom no other treatment option exists.

Published
2005
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results